Angiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure
Results of this cross-sectional study reveal that in the 7 years after FDA drug approval of sacubitril-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge increased, and rates of ACEI or ARB prescription decreased. Overall prescription of ARNI at discharge was 55.4% in eligible patients at the end of the study, suggesting remaining opportunity for continued improvement in ARNI prescription.
Authors
- Alexandra M. Klomhaus (ORCID: https://orcid.org/0000-0002-7676-3595)
- Paul A. Heidenreich (ORCID: https://orcid.org/0000-0001-7730-8490)
- Clyde W. Yancy (ORCID: https://orcid.org/0000-0001-7271-4166)
- Gregg C. Fonarow (ORCID: https://orcid.org/0000-0002-3192-8093)
- Sabra C. Lewsey (ORCID: https://orcid.org/0000-0001-8406-8472)
- Pratyaksh K. Srivastava (ORCID: https://orcid.org/0000-0001-5114-0677)
- Stephen J. Greene
Institutions
- Northwestern University (US)
- Johns Hopkins University (US)
- Duke University (US)
- Johns Hopkins Medicine (US)
- Ronald Reagan UCLA Medical Center (US)
- Clinical Research Institute (US)
- Stanford University (US)
Publication Details
- Journal
- JAMA Cardiology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1001/jamacardio.2024.3815
- Citations
- 2
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.80